Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Immatics N.V.NASDAQ: IMTX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of €7.61M fell 59.0% year over year, ahead of the -74.1% change in trailing-twelve-month revenue. Sequentially, it fell 61.5% from the prior quarter. Over 3 fiscal years it compounded at -34.6% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of €36.14M (-25.1%) for the fiscal year ending Dec 2026, a step up from the -69.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
€7.61M-61.5% QoQ
Last fiscal yearDec 2025
€48.27M-69.0% YoY
LTMMar 2026
€37.3M-74.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.0%+151.3%+210.3 pp
1 year-69.0%-25.1%+43.9 pp
3-year CAGR-34.6%+34.4%+69.1 pp
5-year CAGR+55.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

EUR · from the income statement

Latest · FY2025
48.27M EUR
Year-over-year change
-69.0%
4-year CAGR
+8.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -74.1% is the 9th highest of 10, against a peer median of +15.6%.
  • Over three fiscal years its annual growth of -34.6% compares with a peer median of +10.9%.
IMTX Competitors
Revenue for IMTX and competitors
Company Period LTM YoY 3-year CAGR
BNTXBioNTech SELTM Jun 2026€2.64B EUR-8.2%-45.8%
LEGNLegend Biotech CorporationLTM Sep 2026$1.36B USD+49.5%+106.4%
IMCRImmunocore Holdings plcLTM Mar 2026$385.76M USD+15.6%+27.3%
CLLSCellectis S.A.LTM Mar 2026$68.09M USD+42.9%+56.1%
DTILPrecision BioSciences, Inc.LTM Mar 2026$45.07M USD-11.9%+10.9%
IMTXImmatics N.V.LTM Mar 2026€37.3M EUR-74.1%-34.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$23.14M USD-88.4%+23.9%
JANXJanux Therapeutics, Inc.LTM Mar 2026$21.61M USD+131.5%+5.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$9.14M USD+106.7%-8.6%
LYELLyell Immunopharma, Inc.LTM Mar 2026$31K USD-52.3%-92.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD——
Peer median (excluding IMTX) —+15.6%+10.9%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.76M172.83M54M155.84M48.27M
Cost of Revenue87.57M106.78M118.66M00
Gross Profit(52.81M)66.05M(64.67M)155.84M48.27M
Gross Margin-151.9%38.2%-119.8%100.0%100.0%
Research & Development87.57M106.78M118.66M148.08M183.83M
Selling, General & Admin33.81M36.12M38.2M46.45M51.18M
Operating Expenses121.05M142.88M155.72M194.45M230.28M
Depreciation & Amortization5.47M6.84M7.23M12.23M12.4M
EBITDA(87.3M)50.04M(88.93M)34.46M(185.09M)
EBITDA Margin-251.1%29.0%-164.7%22.1%-383.5%
Operating Income(86.29M)29.95M(101.73M)(38.62M)(182.02M)
Operating Margin-248.2%17.3%-188.4%-24.8%-377.1%
Interest Income133K2.48M13.85M25M17.18M
Interest Expense566K1.04M831K886K946K
Other Income / Expenses(7.04M)12.08M4.73M59.96M(16.42M)
Income Before Tax(93.34M)42.04M(96.99M)21.35M(198.44M)
Pre-Tax Margin-268.5%24.3%-179.6%13.7%-411.1%
Income Tax Expense04.55M06.13M(1.99M)
Net Income(95.06M)37.51M(96.99M)15.22M(196.45M)
Net Margin-273.5%21.7%-179.6%9.8%-407.0%
EPS (Basic)(1.51)0.55(1.20)0.14(1.54)
EPS (Diluted)(1.51)0.54(1.20)0.14(1.54)
Weighted Avg Shares62.91M67.22M80.55M108.7M122.35M
Weighted Avg Shares (Diluted)62.91M68.82M80.55M106.8M122.35M

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.